The Predictive Value of the Dexamethasone Suppression Test

Peselow, Eric D.; Stanley, Michael; Filippi, Ann-Marie; Barouche, Faouzia; Goodnick, Paul J.; Fieve, Ronald R.

doi:10.1192/bjp.155.5.667

Cited by 7 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First-generation antipsychotics were used as antidepressants mainly for mixed anxiety-depressive states 6 . Benzamides, especially sulpiride, has actually been a treatment option for depression 7 8 . Recently, several randomized controlled trials (RCTs) have compared the effectiveness, efficacy, and safety of APM in patients with MDD.…”

Section: Introductionmentioning

confidence: 99%

Antipsychotic Monotherapy for Major Depressive Disorder: A Systematic Review and Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

Although several randomized controlled trials (RCTs) have compared the effectiveness, efficacy, and safety of antipsychotic monotherapy (APM) versus placebo in patients with major depressive disorder (MDD), no meta-analysis has examined this topic. We conducted a systematic literature search using MEDLINE and Embase to identify relevant RCTs and performed a meta-analysis to compare the following outcomes between APM and placebo: response and remission rates, study discontinuation due to all causes, lack of efficacy, and adverse events, changes in total scores on depression severity scales, and individual adverse event rates. A total of 13 studies were identified, with 14 comparisons involving 3,197 participants that met the eligibility criteria. There were significant differences between APM and placebo in response and remission rates and changes in the primary depression severity scale in favor of APM, and study discontinuation due to adverse events and several individual adverse events in favor of placebo. No significant difference was observed in discontinuation due to all causes. APM could have antidepressant effects in the acute phase of MDD, although clinicians should be aware of an increased risk of some adverse events.

show abstract

Section: Introductionmentioning

confidence: 99%

Antipsychotic Monotherapy for Major Depressive Disorder: A Systematic Review and Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

Placebo Response in Studies of Major Depression

Walsh¹,

Seidman

Sysko³

et al. 2002

JAMA

1,048

665

View full text Add to dashboard Cite

The response to placebo in published trials of antidepressant medication for MDD is highly variable and often substantial and has increased significantly in recent years, as has the response to medication. These observations support the view that the inclusion of a placebo group has major scientific importance in trials of new antidepressant medications and indicate that efforts should continue to minimize the risks of such studies so that they may be conducted in an ethically acceptable manner.

show abstract